Objective: To study the therapeutic effect of Lamiophlomis Rotata Capsule (LRC) in the treatment of type ⅢB prostatitis.
Methods: We randomly divided 225 patients with type ⅢB prostatitis into an experimental group (n =125) and a control group (n =120), the former treated orally with LRC at 3 capsules tid while the latter with tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd, both for 4 weeks. We compared the therapeutic effects between the two groups of patients based on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) obtained before, immediately after and at 4 weeks after medication.
Results: A total of 120 patients completed the treatment in the experimental group, which showed remarkable decreases as compared with the baseline in the pain score (5.30 ± 1.23 vs 14.68 ± 1.51, P<0.05), quality of life (QoL) score (6.46 ± 0.93 vs 8.52 ± 1.05, P<0.05) and total NIH-CPSI score (17.50 ± 2.77 vs 27.99 ± 2.98, P<0.05) after 4 weeks of treatment, but no significant change in the urination symptoms score (7.41 ± 1.16 vs 7.16 ± 1.04, P>0.05). The experimental group achieved even markedly lower scores than the controls in the pain symptom (5.30 ± 1.23 vs 13.67 ± 1.49, P<0.05), QoL (6.46 ± 0.93 vs 7.47 ± 0.88, P<0.05) and total NIH-CPSI (17.50 ± 2.77 vs 25.77 ± 2.01, P<0.05) but a higher urination symptoms score than the latter after medication (7.16 ± 1.04 vs 5.68 ± 1.34, P<0.05). At 4 weeks after drug withdrawal, the experimental group also showed significantly lower scores of the pain symptom (7.23 ± 1.03), QoL (6.58 ± 0.87) and total NIH-CPSI (22.18 ± 2.03) than the baseline (all P<0.05) and those in the control group (14.14 ± 0.98, 8.12 ± 0.72 and 26.89 ± 1.67) (all P<0.05). Apart from dizziness in 2 of the patients, who gave up medication halfway, no other obvious adverse reactions were observed during the experiment.
Conclusions: Lamiophlomis Rotata Capsule deserves to be recommended for the treatment of type ⅢB prostatitis for its safety and effectiveness in reducing the pain and improving the life quality of the patients.
目的: 探讨独一味胶囊治疗ⅢB型前列腺炎的疗效。 方法: 选择ⅢB型前列腺炎患者225例，随机分为两组：治疗组125例，口服独一味胶囊，一次3粒，一日3次，疗程4周；对照组100例，口服盐酸坦索罗辛缓释胶囊，0.2 mg/次，一日1次，疗程4周。以NIH-CPSI评分为疗效评价指标，比较治疗前后、停药4周后两组的疗效。 结果: 治疗组完成治疗 １２０ 例，结果示：①治疗组治疗后疼痛症状评分、生活质量评分和总评分均较治疗前显著下降（5.30±1.23 vs 14.68±1.51； 6.46±0.93 vs 8.52±1.05； 17.50±2.77 vs 27.99±2.98）（P<0.05）；而排尿症状评分治疗前后无明显改变（7.41±1.16 vs 7.16±1.04）（P > 0.05）。 ②治疗组治疗后疼痛症状评分、生活质量评分和总评分均较对照组治疗后评分低（5.30±1.23 vs 13.67±1.49；6.46±0.93 vs 7.47±0.88； 17.50±2.77 vs 25.77±2.01 ）（P<0.05）；而排尿症状评分对照组较治疗组低（5.68±1.34 vs 7.16±1.04）（P<0.05）。③停药 ４ 周后，治疗组疼痛症状评分、生活质量评分和总评分，比治疗前仍显著下降（7.23±1.03 vs 14.68±1.51； 6.58±0.87 vss 8.52±1.05； 22.18±2.03 vs 27.99±2.98）（P<0.05）；同时也明显低于对照组撤药后评分（7.23±1.03 vs 14.14±0.98； 6.58±0.87 vs 8.12±0.72； 22.18±2.03 vs 26.89±1.67）（P<0.05）。④治疗组因为头晕不适退出治疗 ２ 例，失联 ３例，其余患者未见明显不良事件发生。结论: 独一味胶囊在改善ⅢB型前列腺炎患者疼痛症状及生活质量上安全、有效，有临床应用价值。.
Keywords: pain; prostatitis; treatment; Lamiophlomis Rotata Capsule.